Officials will use participation as evidence that the process was inclusive and broadly supported. That claim provides procedural cover for inaction, allowing officials to present incremental adjustments as stakeholder-supported reform. The Delphi studies will be weaponised as a durable rhetorical shield against renewed scrutiny. There are options.
Stakeholders must act to protect their voice in response to the risk of a manufactured consensus
May 7, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
Territory partnership backs digital health push for diabetes, kidney and heart care
July 9, 2026 - - Latest News -
It might make sense to follow the process, mostly, but no need to keep patients waiting
July 9, 2026 - - Latest News -
Illumina taps medtech leader to head Australia and New Zealand operations
July 8, 2026 - - Latest News -
PYC Therapeutics names Thomas Ulmer as new chief financial officer
July 8, 2026 - - Australian Biotech -
In a perfect world, the minister would not be in this position, and he might question the timeline
July 8, 2026 - - Latest News -
Aegros completes Australia’s second large scale plasma fractionation plant
July 8, 2026 - - Latest News -
'But I've said it's really important that these two drugs stay on the PBS'
July 7, 2026 - - Latest News

